Osiris Therapeutics, Inc. (OSIR) Release: Grafix® Pharmacoeconomic And Scientific Characterization Studies Featured At The 2014 Spring Symposium For Advanced Wound Care
4/24/2014 7:35:11 AM
Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced today that results from both a pharmacoeconomic evaluation and a scientific characterization (cryopreservation versus non-cryopreservation) of Grafix® will be presented at the 2014 Spring Symposium on Advanced Wound Care (SAWC) in Orlando.
The pharmacoeconomic evaluation study focuses on the economic advantages that Grafix provides using claims data, including discharge information from over 6.9 million patients (DRG Summary for Medicare Inpatient Prospective Payment Hospitals) and clinical data from Osiris’ multi-center, randomized, controlled clinical trial evaluating the safety and effectiveness of Grafix in patients with chronic diabetic foot ulcers (DFU).
Help employers find you! Check out all the jobs and post your resume.
comments powered by